ORYZF (Oryzon Genomics) 3-1 Month Momentum %: 9.13% (As of Jul. 20, 2026)

Author: Vera Yuan Vera Yuan
Vera Yuan
Vera Yuan
Director of Data and Quant Analytics at GuruFocus
Focused on building reliable datasets, financial models, and research tools for value-minded investors. Committed to turning complex data into practical guidance for value-investing and long-term wealth.
Reviewed by: Charlie Tian Charlie Tian
Charlie Tian
Charlie Tian
Founder & CEO of GuruFocus
Dr. Charlie Tian is the founder and CEO of GuruFocus.com, a leading global investment research platform established in 2004. With a Ph.D. in physics, Dr. Tian transitioned from science to finance, applying a data-driven, disciplined approach to value investing.

ORYZF Oryzon Genomics SA ORYZF
33 GF Score
Price $3.66
View Full Analysis

What is Oryzon Genomics 3-1 Month Momentum %?

Oryzon Genomics ORYZF 33 3-1 Month Momentum % is 9.13% as of Jul. 20, 2026. GuruFocus rates ORYZF with a GF Score™ of 33/100. Among 1,386 Biotechnology companies, Oryzon Genomics ranks better than 83.91% on this metric.

3-1 Month Momentum % is the total return of the stock from 3-month ago to 1-month ago. As of today (2026-07-20), Oryzon Genomics's 3-1 Month Momentum % is 9.13%.

The industry rank for Oryzon Genomics's 3-1 Month Momentum % or its related term are showing as below:

ORYZF's 3-1 Month Momentum % is ranked better than
83.91% of 1386 companies
in the Biotechnology industry
Industry Median: -13.61 vs ORYZF: 9.13

Oryzon Genomics  (OTCPK:ORYZF) 3-1 Month Momentum % Explanation

Momentum investing is a trading strategy in which investors buy securities that are rising and sell before the prices start to go back down. The 3-1 Month Momentum % measures the total return to a stock over the past three months, but ignores the previous month.

The reason why the most recent month’s return dropped related to the short-term reversal effect associated with momentum. There is an academic finding that short-term momentum actually has a reversal effect, whereby the previous winners (measured over the past months) do poorly the next month, while the previous losers do well the next month. In order to eliminate the short-term reversal effect, the previous month return was not included in this calculation.

Oryzon Genomics 3-1 Month Momentum % Related Terms

ORYZF vs VRTX, REGN, ALNY: 3-1 Month Momentum % Comparison

For the Biotechnology subindustry, Oryzon Genomics's 3-1 Month Momentum %, along with its competitors' market caps and 3-1 Month Momentum % data, can be viewed below:

* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.

Oryzon Genomics 3-1 Month Momentum % vs Biotechnology Industry

For the Biotechnology industry and Healthcare sector, Oryzon Genomics's 3-1 Month Momentum % distribution charts can be found below:

* The bar in red indicates where Oryzon Genomics's 3-1 Month Momentum % falls into.


ORYZF
33GF Score
Oryzon Genomics SA ORYZF
3-1 Month Momentum % is just one metric. See GF Score™, valuation, warning signs, and more.
View Full Analysis

Oryzon Genomics  (OTCPK:ORYZF) 3-1 Month Momentum % Calculation

3-1 Month Momentum % is calculated as following:

3-1 Month Momentum %=( Price 1-month ago / Price 3-month ago - 1 ) * 100 %

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

Frequently Asked Questions Learn more about 3-1 Month Momentum % →
What does a 3-1 Month Momentum % of 9.13% mean?
Oryzon Genomics (ORYZF) has a 3-1 Month Momentum % of 9.13% as of Jul. 20, 2026. 3-1 Month Momentum measures the total return of the stock from 3-month ago to 1-month ago. View historical data on Oryzon Genomics and its competitors. According to the industry distribution chart, Oryzon Genomics ranks #223 out of 1386 companies in the Biotechnology industry, placing it in the top 16.1%.
Is Oryzon Genomics' 3-1 Month Momentum % too high?
Oryzon Genomics' current 3-1 Month Momentum % is 9.13%. Based on the distribution chart, Oryzon Genomics ranks #223 out of 1386 companies in the Biotechnology industry, which is in the top quartile — a strong position relative to peers. Overall, Oryzon Genomics has a GF Score™ of 33/100, reflecting its overall financial health beyond just this single metric.
How does Oryzon Genomics' 3-1 Month Momentum % compare to VRTX and REGN?
According to the Biotechnology industry distribution chart, Oryzon Genomics ranks #223 out of 1386 companies for 3-1 Month Momentum %. This places Oryzon Genomics in the top 16% of its industry — outperforming the majority of peers. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good 3-1 Month Momentum % for a Biotechnology company?
A good 3-1 Month Momentum % depends on the Biotechnology industry context. However, 3-1 Month Momentum % should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high 3-1 Month Momentum % mean?
A high 3-1 Month Momentum % can signal that a stock is expensive relative to its fundamentals. 3-1 Month Momentum measures the total return of the stock from 3-month ago to 1-month ago. View historical data on Oryzon Genomics and its competitors. Oryzon Genomics's current 3-1 Month Momentum % is 9.13%. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is Oryzon Genomics stock overvalued right now?
Oryzon Genomics (ORYZF) has a current 3-1 Month Momentum % of 9.13%. The current 3-1 Month Momentum % is 9.13%. Oryzon Genomics' overall GF Score™ is 33/100. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is 3-1 Month Momentum % calculated?
3-1 Month Momentum % is calculated from a company's financial statements. For Oryzon Genomics (ORYZF), the current 3-1 Month Momentum % is 9.13% as of Jul. 20, 2026. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.

Oryzon Genomics Business Description

Other Exchanges 0RDB:UKORY:SpainORN:Germany
Address Sant Ferran 74, Cornellà de Llobregat, Barcelona, ESP, 08940
Oryzon Genomics SA is a clinical stage biopharmaceutical company and engaged in the development of epigenetics-based therapeutics. It is engaged in the field of epigenetic medicine and in the development of therapeutic, biological solutions for cancer and neurodegenerative diseases.
33GF Score

Get the complete analysis for ORYZF

3-1 Month Momentum % is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.

$3.66
Price